Moderna Surges 119% on Cancer Vaccine, Estee Lauder Rises 16% on Earnings
0h ago|5 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
modernaestee-lauder
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. AiX is informational software — not investment advice. Past performance does not guarantee future results.
Moderna Inc. (MRNA) shares recorded a historic intraday gain of 119% on Wednesday, August 19, 2026, following positive late-stage trial results for its personalized cancer vaccine. Estee Lauder Companies Inc. (EL) rallied 16.18% after reporting fourth-quarter earnings that exceeded analyst expectations. La-Z-Boy Incorporated (LZB) shares declined 17.89% after the furniture maker's sales forecast fell short of estimates. Bloomberg reported the news based on company statements and market data.
Moderna's surge represents the largest single-day gain in the company's history, a milestone for a firm previously propelled to prominence by its COVID-19 vaccine. The successful Phase 3 trial data for mRNA-4157 (V940), developed in partnership with Merck & Co. (MRK), validates the application of mRNA technology beyond infectious diseases into oncology. This breakthrough arrives during a period of heightened investor focus on innovative cancer treatments and weight-loss drugs, sectors that have commanded significant market attention and capital flows throughout 2026. The specific catalyst was the announcement that the combination therapy demonstrated a statistically significant improvement in reducing the risk of recurrence of melanoma versus Keytruda alone.
Estee Lauder's positive earnings surprise indicates a potential turnaround for the prestige beauty giant, which had faced headwinds from sluggish demand in key Asian markets and inventory destocking throughout much of 2025. The company's improved guidance for fiscal 2027 suggests management confidence in a recovery in consumer spending, particularly in travel retail and mainland China. This report provides a counter-narrative to concerns over discretionary consumer spending resilience amid fluctuating macroeconomic conditions.
La-Z-Boy's forecast miss highlights ongoing challenges within the consumer discretionary and home furnishings sector. High interest rates have continued to pressure housing activity and demand for big-ticket items, creating a difficult environment for manufacturers and retailers. The company's performance serves as a real-time indicator of consumer sensitivity to economic pressures and shifting spending priorities away from home improvement.
Moderna's stock price reached $141.16 as of 15:56 UTC today, after trading in a wide range between $114.46 and $163.47. The 119% appreciation added approximately $55 billion to the company's market capitalization in a single session. Partner Merck & Co. also saw significant buying interest, with its shares advancing 10.10% to $149.70. This performance dramatically outpaces the broader healthcare sector and the Nasdaq Biotechnology Index, which were up marginally on the day.
Estee Lauder shares traded at $97.99, near the top of its daily range of $93.97 to $99.81. The company's fourth-quarter adjusted earnings per share and revenue metrics surpassed consensus estimates compiled by Bloomberg. More importantly, the midpoint of the company's fiscal 2027 organic sales growth and adjusted EPS guidance ranges exceeded Street views, signaling confidence in sustained recovery.
La-Z-Boy shares declined to $34.09, near the bottom of its $33.52 to $36.50 trading range. The company's second-quarter sales forecast missed the average analyst estimate, reflecting persistent softness in consumer demand for furniture. The stock's decline contrasts with the performance of the broader consumer discretionary sector, which was flat to slightly positive on the session.
| Company | Ticker | Price | % Change | Key Catalyst |
|---|---|---|---|---|
| Moderna | MRNA | $141.16 | +119% | Positive Phase 3 cancer vaccine data |
| Estee Lauder | EL | $97.99 | +16.18% | Q4 earnings beat, strong guidance |
| La-Z-Boy | LZB | $34.09 | -17.89% | Q2 sales forecast miss |
The dramatic move in Moderna shares reflects both the clinical significance of the trial results and the substantial commercial opportunity in oncology immunotherapy. The successful application of mRNA technology to cancer treatment could open a new multibillion-dollar market for Moderna, reducing its dependency on COVID-related revenue. Merck stands to benefit significantly as well, as the combination therapy could expand the use and duration of treatment with its blockbuster drug Keytruda, potentially extending its patent-protected revenue stream.
The rally in biotechnology stocks extended beyond Moderna and Merck, with the XBI biotech ETF climbing approximately 5% on the session. Companies developing competing oncology immunotherapies, particularly those focused on personalized cancer vaccines, saw increased investor interest. Conversely, developers of traditional chemotherapies and less differentiated oncology treatments may face increased competitive pressures should mRNA-based approaches gain regulatory approval and market adoption.
A counter-argument to the bullish thesis involves the regulatory pathway ahead. While the Phase 3 data are impressive, full approval from the FDA and other global regulators remains pending and is not guaranteed. Commercialization timelines, pricing negotiations with payers, and market adoption rates all present execution risks that could temper long-term revenue projections.
Positioning data indicates heavy institutional buying in Moderna and Merck, with option flow showing concentrated demand for short-dated call options in both names. Hedge funds that were short biotech names into the announcement were forced to cover positions, creating additional upward pressure on share prices throughout the trading session.
Investors will monitor regulatory developments for Moderna and Merck's cancer vaccine combination. The companies are expected to engage with the U.S. Food and Drug Administration regarding a Biologics License Application submission timeline, potentially in the fourth quarter of 2026 or first quarter of 2027. Regulatory decisions in other key markets, including Europe and Japan, will follow thereafter.
For Estee Lauder, the key catalyst will be the company's next earnings report in November 2026, which will provide evidence of whether the guidance upgrade is supported by actual demand recovery. Markets will particularly watch for improvements in Asian retail sales data and travel retail channel performance in the intervening months.
La-Z-Boy's next meaningful update will be its second-quarter earnings release, expected in November 2026. Traders will watch for any revisions to full-year guidance and commentary on order trends, which could indicate whether the softness is company-specific or industry-wide. Key levels to watch for the stock include the $32 support level, which held during previous selloffs in 2025.
The Phase 3 trial demonstrated that Moderna's personalized cancer vaccine combined with Merck's Keytruda significantly reduced the risk of recurrence or death in patients with stage III/IV melanoma compared to Keytruda alone. This represents a potential paradigm shift in adjuvant treatment for high-risk melanoma, moving toward highly personalized immunotherapy approaches that train the immune system to target patient-specific tumor mutations. The treatment could become a new standard of care if approved by regulators.
Estee Lauder's better-than-expected results and upward guidance revision suggest the company is recovering market share lost during earlier periods of inventory adjustment and soft demand in Asia. The performance indicates that the company's brand strength and product innovation remain competitive despite economic headwinds. If sustained, this recovery could help close the valuation gap with competitors that had executed better during the recent challenging period for prestige beauty.
Intraday moves exceeding 100% for large-cap biotech stocks are exceptionally rare events typically reserved for paradigm-shifting clinical trial results or regulatory decisions. The move echoes significant biotech rallies following positive Phase 3 data for breakthrough therapies in other disease areas, such as the 2013 surge in Vertex Pharmaceuticals following successful cystic fibrosis trial results. Such moves often create sustained sector-wide momentum as investors reassess the commercial potential of emerging technologies.
Moderna's cancer vaccine breakthrough validates mRNA technology beyond infectious diseases and creates substantial value for shareholders.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
AiX is our free MetaTrader 4 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. XAUUSD breakout engine.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.